AMGN vs NVO
Amgen and Novo Nordisk A/S, both Healthcare
Novo Nordisk A/S is the larger company at $211B against $182B. Over the past year AMGN returned +54% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 66 out of 100.
| Figure | AMGN | NVO |
|---|---|---|
| Last close | $415 | $38.62 |
| Market cap | $182B | $211B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 25.8 | n/a |
| Dividend yield | 2.3% | n/a |
| 1-year return | +54% | -35% |
| 5-year return | +122% | -15% |
| RyuScoresector-relative, 1–10 | 66/100 | 88/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Novo Nordisk A/S
Open these two in the interactive comparison to add more names, change the period or see the correlation.